Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
Open Access
- 15 January 2016
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 16 (1) , 1-17
Abstract
The results of observational studies evaluating and comparing the cardiovascular safety of glitazones, metformin and sufonylureas are inconsistent.To conduct and evaluate heterogeneity in a meta-analysis of observational studies on the risk of acute myocardial infarction (AMI) or stroke in patients with type 2 diabetes using non-insulin blood glucose–lowering drugs (NIBGLD). We systematically identified and reviewed studies evaluating NIBGLD in patients with type 2 diabetes indexed in Medline, Embase, or the Cochrane Library that met prespecified criteria. The quality of included studies was assessed with the RTI item bank. Results were combined using fixed- and random-effects models, and the Higgins I 2 statistic was used to evaluate heterogeneity. Sensitivity analyses by study quality were conducted. The summary relative risk (sRR) (95 % CI) of AMI for rosiglitazone versus pioglitazone was 1.13 (1.04–1.24) [I 2 = 55 %]. In the sensitivity analysis, heterogeneity was reduced [I 2 = 16 %]. The sRR (95 % CI) of stroke for rosiglitazone versus pioglitazone was 1.18 (1.02–1.36) [I 2 = 42 %]. There was strong evidence of heterogeneity related to study quality in the comparisons of rosiglitazone versus metformin and rosiglitazone versus sulfonylureas (I 2 ≥ 70 %). The sRR (95 % CI) of AMI for sulfonylurea versus metformin was 1.24 (1.14–1.34) [I 2 = 41 %] and for pioglitazone versus metformin was 1.02 (0.75–1.38) [I 2 = 17 %]. Sensitivity analyses decreased heterogeneity in most comparisons. Sulfonylureas increased the risk of AMI by 24 % compared with metformin; an imprecise point estimate indicated no difference in risk of AMI when comparing pioglitazone with metformin. The presence of heterogeneity precluded any conclusions on the other comparisons. The quality assessment was valuable in identifying methodological problems in the individual studies and for analysing potential sources of heterogeneity.Keywords
This publication has 57 references indexed in Scilit:
- Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysisDiabetic Medicine, 2013
- Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes MellitusAnnals of Internal Medicine, 2012
- Mortality in diabetes compared with previous cardiovascular disease: A gender-specific meta-analysisDiabetes & Metabolism, 2012
- Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese PopulationClinical Therapeutics, 2011
- Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)Pharmacoepidemiology and Drug Safety, 2010
- Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical RecordsDiabetes Care, 2009
- Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case‐control studyPharmacoepidemiology and Drug Safety, 2009
- Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort studyBMJ, 2009
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialThe Lancet, 2009
- An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patientsPharmacoepidemiology and Drug Safety, 2008